VeriStrat^® helps physicians guide therapy.

Some patients with advanced non-small cell lung cancer (NSCLC) respond better to targeted therapies than others.¹ That’s why it’s important for physicians to determine the likelihood of a patient benefitting from EGFR-TKI therapy, such as erlotinib, before determining the treatment path.

VeriStrat is intended for 2nd and 3rd line advanced non-small cell lung cancer(NSCLC) patients who are eligible for EGFR-TKI therapy. VeriStrat provides a clear test result, VeriStrat Good or VeriStrat Poor, that correlates with survival outcomes after EGFR-TKI therapy.² Identifying appropriate patients for 2^nd and 3^rd line therapy is critical to improving patient outcomes. VeriStrat provides health care professionals with the guidance they need to make more informed decisions.

1 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.

2 Carbone D, 2nd European Lung Cancer Conference, April 2010.